Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06760481 · ClinicalTrials.gov registry record · Phase 1
Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)
A Phase 1 study of Advanced Solid Malignancies, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT06760481: Active Phase 1 study of Advanced Solid Malignancies, sponsored by M.D. Anderson Cancer Center.
NCT06760481 is a Phase 1 study of Advanced Solid Malignancies that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 7 participants, below the 244-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06760481, a Phase 1 study of Advanced Solid Malignancies, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
An open-label, Phase I/Ib study investigating the safety and efficacy of tiragolumab + atezolizumab + RadScopal™ XRT in patients with metastatic solid malignancies.
Primary Outcome
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Conditions Studied
Interventions
- DRUG Atezolizumab
- RADIATION Radiation Therapy
- DRUG Tiragolumab
Study Locations (1)
Texas
- The University of Texas M. D. Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2025-04-13 |
| Est. Completion | 2030-09-15 |
| Phase | Phase 1 |
What the registry record for NCT06760481 still lists
NCT06760481 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 244-participant average among 6 other Advanced Solid Malignancies trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Advanced Solid Malignancies appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.
NCT06760481 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06760481 about?
NCT06760481 is a clinical study titled "Phase I/Ib Trial of TIraGolumab, AtEzolizumab, and RadScopal Radiation in Patients With Advanced Solid Malignancies (TIGER)". An open-label, Phase I/Ib study investigating the safety and efficacy of tiragolumab + atezolizumab + RadScopal™ XRT in patients with metastatic solid malignancies.
What is the current status of trial NCT06760481?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2025-04-13. Estimated completion is 2030-09-15.
What conditions does trial NCT06760481 study?
This clinical trial studies the following conditions: Advanced Solid Malignancies.
What interventions are being tested in trial NCT06760481?
The interventions under investigation include: Atezolizumab (DRUG), Radiation Therapy (RADIATION), Tiragolumab (DRUG).
Who is sponsoring clinical trial NCT06760481?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06760481 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies
ACTIVE NOT RECRUITING · Phase 1
-
Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI